Skip to content. Skip to main navigation.

Tethys Bioscience

Investors

Backed by leaders in lifescience investing

Tethys Bioscience is a financially solid company, which has to date raised $103 million. Tethys Bioscience is a privately-held company funded by the following investors:

  • Aeris CAPITAL AG is a venture capital and private equity firm and financial advisor with locations in the United States and Switzerland.

  • Intel Capital is Intel’s global investment organization. The firm makes equity investments in innovative technology start-ups and companies worldwide. Intel Capital invests in a broad range of companies offering hardware, software, and services targeting enterprise, home, mobility, health, consumer Internet, semiconductor manufacturing and cleantech. Since 1991, Intel Capital has invested more than $9.7 billion in over 1,100 companies in 48 countries.

  • Kleiner Perkins Caulfield & Byers (KPCB) is a world-leading venture capital partnership headquartered in the San Francisco Bay Area. Founded in 1972, KPCB focuses primarily on four areas: greentech, information technologies, life sciences and the firm’s own iFund. The firm’s life sciences focus is on devices, diagnostics, therapeutics and healthcare-related tools and services. Highly selective in the companies it invests in, KPCB aims to build “category defining companies” that will become leaders in the field. Since its inception, KPCB has invested in over 475 technology companies.

  • MDV-Mohr Davidow Ventures is a leading Silicon Valley venture capital firm that for over 25 years has applied its expertise in funding and mentoring entrepreneurs, scientists and young companies involved in redefining technology, medicine and business. The firm partners with entrepreneurs to improve healthcare practice through the use of more insightful and personalized information. MDV’s multidisciplinary team engages early in the life of a company to enhance its long-term success. MDV has $2 billion dollars under management.

In July 2010, the company announced it had raised $33 million, comprised of $23 million in venture financing and a $10 million loan. Participants in the venture financing included new investors, Greenspring Associates, Inc. (formerly Montagu Newhall Associates, Inc.) and Paul Capital Investments, as well as all current investors. The loan was provided by Oxford Finance Corporation and Silicon Valley Bank. The additional $23 million brought the total raised in the company’s Series D round to $48 million.

 

Strategically positioned for growth

Tethys continues to assess market conditions and its financing needs and strategies. The company is actively pursuing strategic collaborations that have the potential to increase the rate of market penetration for PreDx® DRS, as well as additional financial support to expand its research, development and commercialization strategies.